We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of certain Alliqua BioMedical, Inc. (NASDAQGS: ALQA) assets to Celularity, Inc. for $29 million in cash.
The investigation concerns whether the Board of Alliqua BioMedical breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Celularity is underpaying for these assets, thus unlawfully harming Alliqua BioMedical shareholders.
To receive more information, please fill out the form.